Presentation is loading. Please wait.

Presentation is loading. Please wait.

Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial  Jonathan M. Spergel,

Published by창민 강 Modified over 5 years ago

Similar presentations

Presentation on theme: "Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial  Jonathan M. Spergel,"— Presentation transcript:

1 Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial  Jonathan M. Spergel, MD, PhD, Marc E. Rothenberg, MD, PhD, Margaret H. Collins, MD, Glenn T. Furuta, MD, Jonathan E. Markowitz, MD, George Fuchs, MD, Molly A. O’Gorman, MD, Juan Pablo Abonia, MD, James Young, MS, Timothy Henkel, MD, PhD, H. Jeffrey Wilkins, MD, Chris A. Liacouras, MD  Journal of Allergy and Clinical Immunology  Volume 129, Issue 2, Pages e3 (February 2012) DOI: /j.jaci Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Randomization scheme and disposition of patients.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Box-and-whisker plot showing peak esophageal eosinophil counts at baseline and end of therapy (EOT; A) and changes from baseline to end of therapy (B). Means are indicated by solid horizontal lines, medians are indicated by dashed lines, interquartile ranges are indicated by shaded boxes, 5th and 95th percentiles are indicated by bars, and points below or above the 5th and 95th percentiles are shown as outliers. P < for all comparisons of reslizumab versus placebo by using a ranked ANCOVA (see the Methods section for details). Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Categorical changes in physician’s eosinophilic esophagitis global assessment scores between baseline and end of therapy. P values from a logistic regression adjusted for the baseline value. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E1 Baseline peak esophageal eosinophil counts (in cells per hpf) versus end-of-therapy counts. Axes are on log scales. Graphs are divided by horizontal and vertical dashed lines that indicate various thresholds: 5 (little or no eosinophil infiltration), 15 (consensus recommendation for diagnosis of eosinophilic esophagitis2,3), 24 (entry criterion for this study), 50, 100, and 150 cells/hpf. The intersections of dashed lines indicating thresholds at baseline and end of therapy create boxes that indicate categorical change. Shading indicates categorical worsening (dark shading), no change (medium shading), or categorical improvement (light shading). Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E2 Frequency of categorical improvement, worsening, or no change in peak esophageal eosinophil counts between baseline and end of therapy, as displayed in Fig E1. P values are from a logistic regression analysis of categorical data adjusted for the baseline value. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial  Jonathan M. Spergel,"

Similar presentations

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Dose-time-response relationship in peanut allergy using a human model of passive cutaneous anaphylaxis  Anja P. Mose, MD, Charlotte G. Mortz, MD, PhD,

Dose-time-response relationship in peanut allergy using a human model of passive cutaneous anaphylaxis  Anja P. Mose, MD, Charlotte G. Mortz, MD, PhD,
Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection  Howard M. Rosenblatt,

Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection  Howard M. Rosenblatt,
Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O

Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O
Winter birth in inner-city asthmatic children is associated with increased food allergen sensitization risk  J. Andrew Bird, MD, Julie Wang, MD, Cynthia.

Winter birth in inner-city asthmatic children is associated with increased food allergen sensitization risk  J. Andrew Bird, MD, Julie Wang, MD, Cynthia.
Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome 

Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome 
Chris A. Liacouras, MD, Glenn T

Chris A. Liacouras, MD, Glenn T
Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels  Miguel L. Stein, MD, Joyce M. Villanueva,

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels  Miguel L. Stein, MD, Joyce M. Villanueva,
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2

Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2
Carol J. Henderson, PhD, RD, J. Pablo Abonia, MD, Eileen C

Carol J. Henderson, PhD, RD, J. Pablo Abonia, MD, Eileen C

Similar presentations

Ads by Google